Lv11
80 积分 2021-12-16 加入
Dozens of new obesity drugs are coming: these are the ones to watch
8天前
已完结
Phase Separation of Chimeric Antigen Receptor Promotes Immunological Synapse Maturation and Persistent Cytotoxicity
15天前
已完结
Charge-based immunoreceptor signalling in health and disease
15天前
已完结
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis
21天前
已完结
Cancer cachexia: molecular mechanisms and treatment strategies
26天前
已完结
First muscle-growing antibody heads to the FDA, with obesity opportunities on the horizon
28天前
已完结
Myostatin/Activin Receptor Ligands in Muscle and the Development Status of Attenuating Drugs
29天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1个月前
已完结
Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)
1个月前
已完结
Mechanisms of cancer cachexia and targeted therapeutic strategies
1个月前
已完结
皖公网安备34019202002308
